(Q27712065)

1

0 references

Beilei Wang

2

0 references

Qiang Wang

3

0 references

Ziping Qi

4

0 references

Lu-Lu Kong

6

0 references

Ji-Yun Chen

7

0 references

Xiaochuan Liu

8

0 references

Aoli Wang

9

0 references

Chen Hu

10

0 references

Wenchao Wang

11

0 references

Huiping Wang

12

0 references

Fan Wu

13

0 references

Yanjie Ruan

14

0 references

Shuang Qi

15

0 references

Juan Liu

16

0 references

Fengming Zou

17

0 references

Zhenquan Hu

18

0 references

Wei Wang

19

0 references

Li Wang

20

0 references

Shanchun Zhang

21

0 references

Cai-Hong Yun

22

0 references

Zhimin Zhai

23

0 references

Jing Liu

24

0 references

Qingsong Liu

Role of ABL family kinases in cancer: from leukaemia to solid tumours

25

0 references

language of work or name

English

0 references

publication date

14 June 2016

0 references

published in

Oncotarget

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Comparative protein modelling by satisfaction of spatial restraints

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Overriding imatinib resistance with a novel ABL kinase inhibitor

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myel

9 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

OpenVirtualToxLab--a platform for generating and exchanging in silico toxicity data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

DOLINA--docking based on a local induced-fit algorithm: application toward small-molecule binding to nuclear receptors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

Bcr-Abl inhibition as a modality of CML therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

The molecular biology of chronic myeloid leukemia.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5216742

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

29 September 2017

1 reference